Selected research
Industry Research
Zonisamide Industry Research Report 2026
Market perspective
The global Zonisamide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Zonisamide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Zonisamide is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Zonisamide is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Zonisamide include APOTEX, Bluepharma, Concordia, Glenmark, Intas Pharmaceuticals, Invagen Pharmaceuticals, Wockhardt, Zydus Pharmaceuticals and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Zonisamide market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Zonisamide Market by Company
APOTEX
Bluepharma
Concordia
Glenmark
Intas Pharmaceuticals
Invagen Pharmaceuticals
Wockhardt
Zydus Pharmaceuticals
Mylan
Sun Pharma
Teva
Eisai
Zonisamide Segment by Type
25mg
50mg
100mg
Zonisamide Segment by Application
Adult
Pediatric
Geriatric
Zonisamide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Zonisamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Zonisamide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Zonisamide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Zonisamide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Zonisamide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Zonisamide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 25mg
- 50mg
- 100mg
Applications
- Adult
- Pediatric
- Geriatric
Companies covered
- APOTEX
- Bluepharma
- Concordia
- Glenmark
- Intas Pharmaceuticals
- Invagen Pharmaceuticals
- Wockhardt
- Zydus Pharmaceuticals
- Mylan
- Sun Pharma
- Teva
- Eisai
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Zonisamide Market Size (2021-2032)
- 2.2.2 Global Zonisamide Sales (2021-2032)
- 2.2.3 Global Zonisamide Market Average Price (2021-2032)
- 2.3 Zonisamide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 25mg
- 2.3.3 50mg
- 2.3.4 100mg
- 2.4 Zonisamide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adult
- 2.4.3 Pediatric
- 2.4.4 Geriatric
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Zonisamide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Zonisamide Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Zonisamide Revenue of Manufacturers (2021-2026)
- 3.4 Global Zonisamide Average Price by Manufacturers (2021-2026)
- 3.5 Global Zonisamide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Zonisamide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Zonisamide, Product Type & Application
- 3.8 Global Manufacturers of Zonisamide, Established Date
- 3.9 Global Zonisamide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 APOTEX
- 4.1.1 APOTEX Company Information
- 4.1.2 APOTEX Business Overview
- 4.1.3 APOTEX Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 APOTEX Zonisamide Product Portfolio
- 4.1.5 APOTEX Recent Developments
- 4.2 Bluepharma
- 4.2.1 Bluepharma Company Information
- 4.2.2 Bluepharma Business Overview
- 4.2.3 Bluepharma Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bluepharma Zonisamide Product Portfolio
- 4.2.5 Bluepharma Recent Developments
- 4.3 Concordia
- 4.3.1 Concordia Company Information
- 4.3.2 Concordia Business Overview
- 4.3.3 Concordia Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Concordia Zonisamide Product Portfolio
- 4.3.5 Concordia Recent Developments
- 4.4 Glenmark
- 4.4.1 Glenmark Company Information
- 4.4.2 Glenmark Business Overview
- 4.4.3 Glenmark Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Glenmark Zonisamide Product Portfolio
- 4.4.5 Glenmark Recent Developments
- 4.5 Intas Pharmaceuticals
- 4.5.1 Intas Pharmaceuticals Company Information
- 4.5.2 Intas Pharmaceuticals Business Overview
- 4.5.3 Intas Pharmaceuticals Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Intas Pharmaceuticals Zonisamide Product Portfolio
- 4.5.5 Intas Pharmaceuticals Recent Developments
- 4.6 Invagen Pharmaceuticals
- 4.6.1 Invagen Pharmaceuticals Company Information
- 4.6.2 Invagen Pharmaceuticals Business Overview
- 4.6.3 Invagen Pharmaceuticals Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Invagen Pharmaceuticals Zonisamide Product Portfolio
- 4.6.5 Invagen Pharmaceuticals Recent Developments
- 4.7 Wockhardt
- 4.7.1 Wockhardt Company Information
- 4.7.2 Wockhardt Business Overview
- 4.7.3 Wockhardt Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Wockhardt Zonisamide Product Portfolio
- 4.7.5 Wockhardt Recent Developments
- 4.8 Zydus Pharmaceuticals
- 4.8.1 Zydus Pharmaceuticals Company Information
- 4.8.2 Zydus Pharmaceuticals Business Overview
- 4.8.3 Zydus Pharmaceuticals Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Zydus Pharmaceuticals Zonisamide Product Portfolio
- 4.8.5 Zydus Pharmaceuticals Recent Developments
- 4.9 Mylan
- 4.9.1 Mylan Company Information
- 4.9.2 Mylan Business Overview
- 4.9.3 Mylan Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Mylan Zonisamide Product Portfolio
- 4.9.5 Mylan Recent Developments
- 4.10 Sun Pharma
- 4.10.1 Sun Pharma Company Information
- 4.10.2 Sun Pharma Business Overview
- 4.10.3 Sun Pharma Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sun Pharma Zonisamide Product Portfolio
- 4.10.5 Sun Pharma Recent Developments
- 4.11 Teva
- 4.11.1 Teva Company Information
- 4.11.2 Teva Business Overview
- 4.11.3 Teva Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Teva Zonisamide Product Portfolio
- 4.11.5 Teva Recent Developments
- 4.12 Eisai
- 4.12.1 Eisai Company Information
- 4.12.2 Eisai Business Overview
- 4.12.3 Eisai Zonisamide Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Eisai Zonisamide Product Portfolio
- 4.12.5 Eisai Recent Developments
5 Global Zonisamide Market Scenario by Region
- 5.1 Global Zonisamide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Zonisamide Sales by Region: 2021-2032
- 5.2.1 Global Zonisamide Sales by Region: 2021-2026
- 5.2.2 Global Zonisamide Sales by Region: 2027-2032
- 5.3 Global Zonisamide Revenue by Region: 2021-2032
- 5.3.1 Global Zonisamide Revenue by Region: 2021-2026
- 5.3.2 Global Zonisamide Revenue by Region: 2027-2032
- 5.4 North America Zonisamide Market Facts & Figures by Country
- 5.4.1 North America Zonisamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Zonisamide Sales by Country (2021-2032)
- 5.4.3 North America Zonisamide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Zonisamide Market Facts & Figures by Country
- 5.5.1 Europe Zonisamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Zonisamide Sales by Country (2021-2032)
- 5.5.3 Europe Zonisamide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Zonisamide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Zonisamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Zonisamide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Zonisamide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Zonisamide Market Facts & Figures by Country
- 5.7.1 South America Zonisamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Zonisamide Sales by Country (2021-2032)
- 5.7.3 South America Zonisamide Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Zonisamide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Zonisamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Zonisamide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Zonisamide Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Zonisamide Sales by Type (2021-2032)
- 6.1.1 Global Zonisamide Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Zonisamide Sales Market Share by Type (2021-2032)
- 6.2 Global Zonisamide Revenue by Type (2021-2032)
- 6.2.1 Global Zonisamide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Zonisamide Revenue Market Share by Type (2021-2032)
- 6.3 Global Zonisamide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Zonisamide Sales by Application (2021-2032)
- 7.1.1 Global Zonisamide Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Zonisamide Sales Market Share by Application (2021-2032)
- 7.2 Global Zonisamide Revenue by Application (2021-2032)
- 7.2.1 Global Zonisamide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Zonisamide Revenue Market Share by Application (2021-2032)
- 7.3 Global Zonisamide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Zonisamide Value Chain Analysis
- 8.1.1 Zonisamide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Zonisamide Production Mode & Process
- 8.2 Zonisamide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Zonisamide Distributors
- 8.2.3 Zonisamide Customers
9 Global Zonisamide Analyzing Market Dynamics
- 9.1 Zonisamide Industry Trends
- 9.2 Zonisamide Industry Drivers
- 9.3 Zonisamide Industry Opportunities and Challenges
- 9.4 Zonisamide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst